A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis - Full Text View

Sponsored by:	CombinatoRx
Information provided by:	CombinatoRx
ClinicalTrials.gov Identifier:	NCT00796211

Purpose

This will be a phase 2a single-center, randomized, blinded, vehicle-controlled exploratory study to assess the activity and safety of CRx-197 in subjects with plaque psoriasis. Approximately 20 male or female subjects with chronic plaque type psoriasis, 18 to 70 years of age, will be included in this study.

All subjects with stable psoriatic plaques will receive all of the following treatments each in a separate test field, once each day for four weeks under occlusion:

CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
0.1% nortriptyline HCl topical cream
0.005% calcipotriol topical cream
Vehicle of CRx-197 topical cream (placebo)

Condition	Intervention	Phase
Plaque Psoriasis	Drug: CRx-197 Drug: Nortriptyline Drug: Calcipotriol Other: Placebo	Phase II

MedlinePlus related topics: Itching Psoriasis

Drug Information available for: Calcipotriene Nortriptyline Nortriptyline hydrochloride Loratadine

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study
Official Title:	A Single-Center, Randomized, Blinded, Vehicle- Controlled Exploratory Study to Assess the Activity of CRx-197 in Subjects With Plaque Psoriasis

Further study details as provided by CombinatoRx:

Primary Outcome Measures:

Safety and tolerability as assessed by treatment emergent adverse events, physical exams, vital signs, concomitant medications/procedures and subject assessment of pruritus [ Time Frame: 6 weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:

Difference in change from baseline in psoriatic infiltrate measured by ultrasound at Days 8, 15, 22, 29 and 43 between CRx-197, nortriptyline, active comparator as well as vehicle of CRx-197 and untreated test field(s) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Differences in change from baseline in erythema measured by chromametry at Days 8, 15, 22, 29 and 43 between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) and normal skin [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]
Modified PASI at Baseline, and Days 8, 15, 22, 29 and 43 between CRx-197, nortriptyline, active comparator, vehicle of CRx-197, untreated test field(s) [ Time Frame: 6 weeks ] [ Designated as safety issue: No ]

Estimated Enrollment:	20
Study Start Date:	November 2008
Study Completion Date:	January 2009
Primary Completion Date:	December 2008 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)	Drug: CRx-197 CRx-197 high dose topical cream (0.1% nortriptyline HCl +0.3% loratadine)
2: Experimental CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)	Drug: CRx-197 CRx-197 low dose topical cream (0.1% nortriptyline HCl + 0.1% loratadine)
3: Active Comparator 0.1% nortriptyline HCl topical cream	Drug: Nortriptyline 0.1% nortriptyline HCl topical cream
4: Active Comparator 0.005% calcipotriol topical cream	Drug: Calcipotriol 0.005% calcipotriol topical cream
5: Placebo Comparator Vehicle of CRx-197 topical cream (placebo)	Other: Placebo Vehicle of CRx-197 topical cream (placebo)

Eligibility

Ages Eligible for Study:	18 Years to 70 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

I01 Subject must voluntarily sign and date the written informed consent prior to any study specific procedures
I02 Subject must be 18 to 70 years of age
I03 Subject must have chronic plaque psoriasis and plaque infiltrates of a thickness of a minimum of 150 µm and stable plaques in an area sufficient for up to five test fields and an untreated control field per each plaque
I04 Subject must be free from a condition/disease that the investigator feels interferes with the interpretation of the study results.
I05 Females of childbearing potential age should either be surgically sterile (hysterectomy or tubal ligation), or should use a highly effective medically accepted contraceptive regimen.

Exclusion Criteria:

E01 Erythrodermic, guttate or pustular psoriasis
E02 Cardiac disease, including recent myocardial infarction, any degree of heart block or other cardiac arrhythmias or valvular heart disease
E03 Mania or acute delirium or epilepsy
E04 Narrow angle glaucoma
E05 Hyperthyroidism by medical history, TSH less than LLN, or a subject receiving thyroid medication
E06 Diabetes
E07 Intolerance to lidocaine
E08 Severe liver disease [ALT laboratory value that exceeds 2.5x ULN]
E09 Known severe kidney disease, acute urinary retention, prostatic hypertrophy with post void residual urine or laboratory value of creatinine that exceeds 1.5x ULN
E10 Significant gastrointestinal disease including but not limited to pyloric stenosis or paralytic ileus
E11 Inflammatory dermatoses except psoriasis; bacterial, viral, or fungal skin infections (at the test plaques); facial rosacea
E12 Active varicella, tuberculosis, syphilis or post-vaccine reactions
E13 Autoimmune disease other than plaque psoriasis (e.g., lupus erythematosis)
E14 Known allergic reactions or hypersensitivity to any of the components of the study treatments
E15 Allergy to adhesives on the templates used in this study
E16 UV therapy or significant UV exposure in the four weeks before treatment application
E17 History of malignancy (except for treated or excised basal cell carcinoma)
E18 History of drug or alcohol abuse (as defined by the Investigator)
E19 Symptoms of a clinically significant illness in the four weeks before treatment application that may influence the outcome of the study
E20 Subject with demonstrated hypercalcemia (calcium greater than ULN) or evidence of Vitamin D toxicity
E21 Subject with demonstrated hypokalemia (less than LLN)

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00796211

Locations

Germany
ProInnovera
Muenster, Germany

Sponsors and Collaborators

CombinatoRx

More Information

Responsible Party:	CombinatoRx ( Alka Batycky, Executive Director, Clinical Programs )
Study ID Numbers:	CRx-197-002
Study First Received:	November 21, 2008
Last Updated:	January 14, 2009
ClinicalTrials.gov Identifier:	NCT00796211
Health Authority:	Germany: Federal Institute for Drugs and Medical Devices

Keywords provided by CombinatoRx:

Psoriasis
CRx-197
nortriptyline
loratadine

CombinatoRx
Dermatology
Erythema
Pruritus

Study placed in the following topic categories:

Calcipotriene
Pruritus
Erythema
Loratadine

Skin Diseases
Psoriasis
Nortriptyline
Skin Diseases, Papulosquamous

Additional relevant MeSH terms:

Neurotransmitter Agents
Neurotransmitter Uptake Inhibitors
Adrenergic Agents
Molecular Mechanisms of Pharmacological Action
Adrenergic Uptake Inhibitors
Physiological Effects of Drugs
Psychotropic Drugs

Pharmacologic Actions
Antidepressive Agents, Tricyclic
Therapeutic Uses
Central Nervous System Agents
Dermatologic Agents
Antidepressive Agents

ClinicalTrials.gov processed this record on January 15, 2009